Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09) : a randomised, multicentre, open-label, phase 3 trial

Weller, Johannes; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Hau, Peter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Brehmer, Stefanie; Bullinger, Lars; Galldiks, Norbert; Schaub, Christina; Kebir, Sied; Stummer, Walter; Simon, Matthias; Fimmers, Rolf; Coch, Christoph; Glas, Martin; Herrlinger, Ulrich; Schaefer, Niklas

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09) : a randomised, multicentre, open-label, phase 3 trial

Autor(en):

Weller, Johannes; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Hau, Peter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Brehmer, Stefanie; Bullinger, Lars; Galldiks, Norbert; Schaub, Christina; Kebir, Sied; Stummer, Walter; Simon, Matthias; Fimmers, Rolf; Coch, Christoph; Glas, Martin; Herrlinger, Ulrich; Schaefer, Niklas

Tübinger Autor(en):

Tabatabai, Ghazaleh

Erschienen in:

Lancet Oncology (2019), Bd. 20, H. 10, S. 1444-1453

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(19)30502-9

ISSN:

1474-5488